Pirfenex Tablet
Pirfenidone
200mg
Cipla Ltd.
| Pack size | 30's |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 35.95 NPR |
Indications
Pirfenex Tablet is used for:
Idiopathic pulmonary fibrosis.
Adult Dose
Oral
Idiopathic pulmonary fibrosis
Adult: Initially, 267 mg tid for 7 days, then increase dose to 534 mg tid for 7 days, then to usual maintenance dose: 801 mg tid. Max: 2403 mg daily. Adjust dosage according to toxicity.
Child Dose
Renal Dose
ESRD requiring haemodialysis: Contraindicated.
CrCl (mL/min) Dosage
<30 Contraindicated.
Administration
Contra Indications
Severe hepatic and renal impairment, ESRD requiring haemodialysis.
Precautions
Smokers. Mild to moderate hepatic and renal impairment. Pregnancy and lactation. Patient taking fluvoxamine and ciprofloxacin.
Pregnancy-Lactation
Interactions
Increased toxicity with strong (e.g. fluvoxamine) and moderate (e.g. ciprofloxacin) CYP1A2 inhibitors. Decreased efficacy with CYP1A2 inducers (e.g. omeprazole).
Adverse Effects
Side effects of Pirfenidone :
Significant: Nausea, vomiting, diarrhoea, dyspepsia, GERD, abdominal pain, photosensitivity, weight loss, dizziness, increased ALT/AST, angioedema. Rarely, hyperbilirubinaemia.
Gastrointestinal disorders: Constipation, flatulence, gastritis.
General disorders and administration site conditions: Fatigue, asthenia, lethargy, non-cardiac chest pain.
Investigations: Increased γ-glutamyl transferase.
Metabolism and nutrition disorders: Anorexia, decreased appetite.
Musculoskeletal and connective tissue disorders: Myalgia, arthralgia.
Nervous system disorders: Headache, dysgeusia.
Psychiatric disorders: Insomnia, somnolence.
Renal and urinary disorders: UTI.
Respiratory, thoracic and mediastinal disorders: Dyspnoea, cough, upper respiratory tract infection.
Skin and subcutaneous tissue disorders: Rash, pruritus, erythema, dry skin, sunburn.
Vascular disorders: Hot flush.
Mechanism of Action
Pirfenidone, a synthetic pyridone, is an antifibrotic agent. Its exact mechanism of action is still unknown. In idiopathic pulmonary fibrosis, it may decrease the amount of pro-inflammatory cells [e.g. interleukin-1-β (IL-1β), IL-6, tumour necrosis factor-α (TNF-α)] and the production of fibroblast and of fibrosis-associated proteins and cytokines. It may also decrease accumulation of extracellular matrix and lung fibrosis due to transforming growth factor-β (TGF-β) and platelet derived growth factor (PDGF).
Note
Pirfenex 200mg Tablet manufactured by Cipla Ltd.. Its generic name is Pirfenidone. Pirfenex is availble in Nepal.
Farmaco Nepal drug index information on Pirfenex Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.